Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.

Duvic, Madeleine; Pinter-Brown, Lauren C; Foss, Francine M; Sokol, Lubomir; Jorgensen, Jeffrey L; Challagundla, Pramoda; Dwyer, Karen M; Zhang, Xiaoping; Kurman, Michael R; Ballerini, Rocco; Liu, Li; Kim, Youn H.
Blood; 125(12): 1883-9, 2015 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-25605368